ARTICLE | Company News
CytRx, Orphazyme deal
May 23, 2011 7:00 AM UTC
Orphazyme said the technology complements its development of heat shock protein-based therapies for lysosomal storage diseases, including lead compound Orph-001, a recombinant version of the molecular chaperone heat shock protein 70 (Hsp70) in preclinical testing. ...